In the race to find new ways to prevent and treat COVID-19, CCTG has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients.
CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer.
CCTG would like to extend condolences to the family, friends, and colleagues of Dr. Libni Joseph Eapen who passed suddenly last week. Dr. Eapen was a researcher and radiation oncologist at the Ottawa Cancer Centre for the entirety of his career, he dedicated his 66 years to learning, teaching, humour and healing.
Published: September 09, 2020
OV19: A Randomized, Two-Arm, Multi-Centre Gynecologic Cancer Intergroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) In Patients with Epithelial Ovarian Cancer
JBR10: Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10
MAP3: A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
CE6: A Randomized Phase III Study Of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients
BR18: A Phase II/III Double Blind Randomized Trial of BMS-275291 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of
Advanced or Metastatic Non-Small Cell Lung Cancer
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy.